Last reviewed · How we verify
Postoperative epidural morphine
Postoperative epidural morphine is a Small molecule drug developed by Northern Orthopaedic Division, Denmark. It is currently in Phase 1 development. Also known as: Convalescence after lumbar fusion.
Postoperative epidural morphine is used to treat pain after various surgeries, including colon cancer surgery, thoracotomy, and cancer debulking. It is administered via epidural analgesia, a method of pain relief that involves injecting medication into the epidural space surrounding the spinal cord.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Postoperative epidural morphine |
|---|---|
| Also known as | Convalescence after lumbar fusion |
| Sponsor | Northern Orthopaedic Division, Denmark |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Intercostal Nerve Cryoablation Versus Epidural Analgesia for Nuss Repair of Pectus Excavatum (NA)
- Continous Infusion of Nefopam for Patients Undergoing Pancreatoduodenectomy (PHASE4)
- General Anesthesia and General Anesthesia Combined With Thoracic Epidural Anesthesia (NA)
- Spinal Anesthesia For Enhanced Recovery After Liver Surgery (NA)
- Intrathecal Versus Epidural Morphine for Post-Cesarean Analgesia (PHASE4)
- An Artificial Intelligence Driven Approach to Optimize Patient Selection for a Transitional Pain Service (PHASE3)
- Continuous Wound Catheter Analgesia Associated With Intravenous Morphine PCA After Thoracotomy (PHASE4)
- Paravertebral Analgesia Associated With Intravenous Morphine PCA After Thoracotomy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Postoperative epidural morphine CI brief — competitive landscape report
- Postoperative epidural morphine updates RSS · CI watch RSS
- Northern Orthopaedic Division, Denmark portfolio CI
Frequently asked questions about Postoperative epidural morphine
What is Postoperative epidural morphine?
Who makes Postoperative epidural morphine?
Is Postoperative epidural morphine also known as anything else?
What development phase is Postoperative epidural morphine in?
Related
- Manufacturer: Northern Orthopaedic Division, Denmark — full pipeline
- Also known as: Convalescence after lumbar fusion
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing